Common Stock
/PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T cell therapies for the treatment of...
Phase 1/2 TCR-T Library trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications is open for enrollment; continue to expect to dose...
ZIOPHARM Oncology (ZIOP) has been struggling lately, but the selling pressure may be coming to an end soon.
HOUSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced the presentation of...
HOUSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced financial results for...
HOUSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced that it will report...
Are short squeeze penny stocks part of your Q4 strategy?
Futures are up over 0.4% in the pre-market sessions and it looks like it will be a bull's day today. Futures on the Dow Jones Industrial Average gained 151 poi
Ziopharm's (ZIOP) stock price falls after the announcement of several restructuring changes to advance the TCR program.
Recent insider stock purchases were more than a little encouraging.
Investors need to pay close attention to ZIOPHARM (ZIOP) stock based on the movements in the options market lately.